An interventional study of Phototherapy in Dementia, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Dementia by Mayo Clinic — 6 open to participants now, 6 under way, none of them phase 3. Dementia · Mayo Clinic.
Among the 14 studies in Dementia by Mayo Clinic, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 8 with no phase, and was the 14th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →6 of the 14 studies in Dementia by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 50–90
Mayo Clinic · Sites in United States
Ages 40–90 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 30+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 40–90
Mayo Clinic · Sites in United States
Ages 30–100 · Healthy volunteers
By country, each count listing its studies:
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 60 across the 14 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
4 of the studies in Dementia by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01453127Mayo ClinicDaTSCAN Imaging in Aging and Neurodegenerative Disease | 2026-12 |
| NCT07488195Mayo ClinicA Study Of Phototherapy In Patients With Dementia To Improve BPSD | 2026-12-31 |
| NCT00950430Mayo ClinicImaging of Brain Amyloid Plaques in the Aging Population | 2027-06 |
| NCT05514106Mayo ClinicMIBG in Aging and Neurologic Disorders | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Dementia by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to determine whether the use of phototherapy can help reduce behavioral and psychological symptoms, including agitation in people with dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in the phototherapy arm will receive bright light therapy for 60 minutes, 3 times per day for 5 days.
Other: Phototherapy
Patients in the standard of care group will not receive an intervention.
Bright light therapy will be provided via the Verilux HappyLight. The unit will be placed on a mobile bedside table, at eye level, 60 cm from the patient. Patients will receive phototherapy in 60 minute sessions, 3 times daily for 5 days.
Feasibility of 5-day phototherapy protocol
Feasibility will be defined as the percentage of eligible patients who choose to enroll in the study out of total patients approached.
Time frame: Day 5
Acceptability of 5-day phototherapy protocol
Accessibility will be defined as the percentage of study participants to complete at least one session per day of the 5-day protocol
Time frame: Day 5
Tolerability of 5-day phototherapy protocol
Tolerability will be defined as percentage of patients to rate phototherapy as 'very tolerable' based on being asked "Considering all aspects of your experience, how would you rate the overall tolerability of the phototherapy?" The response options are: very tolerable, somewhat tolerable, neutral, somewhat intolerable, and very intolerable.
Time frame: Day 5
Sleep duration
Sleep duration will be reported by nursing staff in hours.
Time frame: Day 5
Plan to share: No
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 2 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.